Life Sciences

  • March 20, 2026

    Former Gilead Sciences GC To Earn Over $2.5M Severance

    Gilead Sciences Inc. is paying its former general counsel more than $2.5 million in severance after she left the company, according to a U.S. Securities and Exchange Commission filing released Friday.

  • March 20, 2026

    CytoDyn Settles Investor Suit With $500K, 49M Shares

    Biotechnology firm CytoDyn has agreed to dole out 49 million shares of common stock and pay $500,000 to end investors' proposed class action accusing the company of overstating the likelihood that the U.S. Food and Drug Administration would approve a drug it claimed could treat HIV and COVID-19.

  • March 20, 2026

    Feds To Cover Ayahuasca Church's Legal Fees, 9th Circ. Says

    The federal government is on the hook for more than $2 million in attorney fees following a settlement with a Phoenix-based church over its right to use the psychedelic beverage ayahuasca in religious ceremonies, a divided Ninth Circuit panel said in an unpublished opinion Friday.

  • March 20, 2026

    EPA's Ethylene Oxide Plan May Hinder Other Air Toxics Regs

    A new proposal from the U.S. Environmental Protection Agency to weaken emission standards for a medical sterilizer could have broader implications for the agency's power to tighten air pollution limits when new science becomes available.

  • March 20, 2026

    Eli Lilly Beats 9th Circ. Appeal Over Brain Bleed After Cialis

    A Ninth Circuit panel Friday upheld Eli Lilly and Co.'s win over a Washington man who claimed the company's erectile dysfunction drug Cialis caused bleeding in his brain, ruling David Dearinger failed to establish that doctors would have acted differently had they been warned of the medication's risks.

  • March 20, 2026

    IVF Patients Say Co. Misled Them On Genetic Test's Accuracy

    A genetic testing company misled consumers about the accuracy and efficacy of a test marketed to patients going through in-vitro fertilization, according to a proposed class action filed in New Jersey federal court.

  • March 20, 2026

    Fed. Circ. Backs Military In Veterinary Software Dispute

    The Federal Circuit on Friday ruled in favor of the government in a dispute with a subcontractor over rights to healthcare software for a U.S. Army veterinary records system, affirming a lower court finding that the contractor failed to present a valid contract claim and could not pursue a copyright infringement claim based on defective registrations.

  • March 20, 2026

    Hims Says Failed Wegovy Collab Doesn't Merit Investor Suit

    Telehealth company Hims & Hers Health Inc. urged a California federal court to release it from a shareholder suit accusing it of exploiting its partnership with Novo Nordisk, the distributor of weight loss drug Wegovy, to sell "knockoff" drugs, saying the suit does not allege the company's executives knew the partnership would fall through.

  • March 20, 2026

    Beasley Allen Can't Halt DQ Ruling In J&J Talc Litigation

    A New Jersey state appeals court has refused to pause its decision disqualifying the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, according to a court order.

  • March 20, 2026

    Hong Kong Backer Accuses Med Co. Founders Of Self-Dealing

    A Hong Kong-based investor has filed a lawsuit in the Delaware Chancery Court accusing the founders of a medical device startup of running the company for their own benefit while ignoring basic corporate governance rules.

  • March 20, 2026

    Prestige Picks Up Breathe Right In $1.05B Deal

    Consumer healthcare company Prestige Consumer Healthcare Inc. revealed on Friday that it has agreed to acquire a portfolio of brands including Breathe Right nasal strips from Foundation Consumer Healthcare, advised by Skadden Arps Slate Meagher & Flom LLP, in a $1.05 billion deal.

  • March 19, 2026

    4th Circ. Leery Of W.Va. Opioid Towns' Abatement Arguments

    During a heated hourlong oral argument Thursday, two Fourth Circuit judges interrogated an attorney for West Virginia municipalities stricken by the opioid crisis about whether the public nuisance of overly available drugs had already been abated, leaving only redress of resulting harms.

  • March 19, 2026

    Chan Zuckerberg Initiative Hit With Gender Bias Action

    The Chan Zuckerberg Initiative LLC run by Meta Platforms Inc. CEO Mark Zuckerberg and his wife Priscilla Chan discriminated against women by routinely paying them less than men and promoting them with less frequency, according to a proposed class and collective action removed Wednesday to California federal court.

  • March 19, 2026

    Pharma Group Can't Halt Colo. Law Over Drug Discount Rules

    A Colorado federal judge denied a bid by the Pharmaceutical Research and Manufacturers of America seeking to halt enforcement of a state law guarding providers' ability to contract with pharmacies to distribute discounted drugs under the federal 340B program.

  • March 19, 2026

    Apple Watch Redesign Gets Early OK As Patent Loss Upheld

    The Federal Circuit on Thursday affirmed a U.S. International Trade Commission decision that found a previous version of the Apple Watch infringes two Masimo blood oxygen monitor patents, but the ruling came one day after an ITC judge said Apple's redesigned version does not infringe those patents.

  • March 19, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Virginia lawmakers last week gave final approval to legislation that would tax and regulate the sale of adult-use cannabis, Georgia legislators passed a dramatic expansion of the state's medical cannabis program, and Iowa lawmakers approved a bill to designate kratom as a Schedule I substance. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • March 19, 2026

    Drug Co. Can't Claim Most Docs Contain Trade Secrets At Trial

    A Manhattan federal judge ruled Thursday that a pharmaceutical consulting company won't be allowed to argue to a jury that thousands of documents it did not enter into evidence contain trade secrets amid an ongoing misappropriation trial.

  • March 19, 2026

    Still No Shenanigans: Fed. Circ. Keeps Review Bar High

    The Federal Circuit's rejection of all mandamus petitions asking it to rein in the way U.S. Patent and Trademark Office leadership is ​evaluating patent challenges cements the appeals court's near-impossible standard for reviewing institution decisions, attorneys say.

  • March 19, 2026

    Calif. Families Sue Rady Health Over Move To End Trans Care

    Four families have asked a state judge to prevent California's largest pediatric health system from cutting off gender-affirming care for minors, alleging the move would violate state antidiscrimination laws and leave them scrambling to find new providers, some more than 100 miles away.

  • March 19, 2026

    Goodwin, S&C Steer Up To $785M Sale Of ADHD Drug

    Goodwin Procter LLP-advised Collegium Pharmaceutical Inc. unveiled plans Thursday to acquire attention deficit hyperactivity disorder drug Azstarys from Sullivan & Cromwell LLP-led Corium Therapeutics Holdings LLC for up to $785 million.

  • March 19, 2026

    CVS, Caremark Pocket Money Meant For Rebates, Suit Claims

    CVS charges drug manufacturers "exorbitant" fees in exchange for pushing their products, then pockets the money instead of funneling it toward customer rebates as it promises, a federal lawsuit alleges, accusing the company of collecting billions of dollars at customers' expense and violating the anti-racketeering statute.

  • March 19, 2026

    Zynex Gets OK For Ch. 11 Plan Reducing Debt By $50M

    Zynex Inc., a pain management medical device maker, received confirmation Thursday of its Chapter 11 plan, which reduces its debt by about $50 million and turns over the company to its creditors.

  • March 18, 2026

    Key Details As 3rd Circ. Ponders FCA's Fate, $1.6B J&J Fine

    Third Circuit judges Wednesday explored divergent views of the False Claims Act's constitutionality and a record fraud verdict against Johnson & Johnson, expressing little eagerness to gut the FCA's whistleblower mechanism, and voicing uncertainty about evidence and jury instructions underpinning the drug promotion punishment.

  • March 18, 2026

    Apple Took Masimo IP But No Remedy Warranted, Judge Says

    A California federal judge determined Apple misappropriated two out of five of Masimo Corp.'s asserted trade secrets related to pulse oximetry technology for its smartwatches, but found Masimo's requests for an injunction and attorney fees unwarranted, according to a December bench trial ruling that was unsealed this week.

  • March 18, 2026

    Stryker Hit With Another Suit After Cyberattack

    Another proposed class action has been filed against Michigan-based medical technology company Stryker Corp. in the wake of a March 11 cyberattack on the company that was reportedly perpetrated by hackers tied to Iran.

Expert Analysis

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

  • 2025's Most Notable State AG Activity By The Numbers

    Author Photo

    State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.

  • Opinion

    The Case For Emulating, Not Dividing, The Ninth Circuit

    Author Photo

    Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.

  • How Rule 16.1 Streamlines And Validates Mass Tort Litigation

    Author Photo

    The new Rule 16.1 of the Federal Rules of Civil Procedure not only serves a practical purpose by endorsing early, structured case management and dispositive motion practice in multidistrict litigation, but also explicitly affirms the importance of MDL practice in the justice system, says Rocco Strangio at Milestone.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.